XL413 (CAS 1169562-71-3)
Alternate Names:
BMS-863233 hydrochloride
CAS Number:
1169562-71-3
Molecular Weight:
326.18
Molecular Formula:
C14H13Cl2N3O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
XL413 is a selective and potent inhibitor of PAK4, a member of the p21-activated kinase (PAK) family. It functions by binding to the ATP-binding site of PAK4, thereby preventing its activation and subsequent downstream signaling. This inhibition of PAK4 activity disrupts its role in regulating cytoskeletal dynamics, cell motility, and cell proliferation. Xl413′s mechanism of action involves blocking the catalytic activity of PAK4, leading to the disruption of its cellular functions.
XL413 (CAS 1169562-71-3) References
- Discovery of XL413, a potent and selective CDC7 inhibitor. | Koltun, ES., et al. 2012. Bioorg Med Chem Lett. 22: 3727-31. PMID: 22560567
- The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. | Sasi, NK., et al. 2014. PLoS One. 9: e113300. PMID: 25412417
- Characterization of a Drosophila ortholog of the Cdc7 kinase: a role for Cdc7 in endoreplication independent of Chiffon. | Stephenson, R., et al. 2015. J Biol Chem. 290: 1332-47. PMID: 25451925
- XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-β1-stimulated C3H10T1/2 cells via Smad2/4. | Jin, SF., et al. 2015. Exp Cell Res. 339: 289-99. PMID: 26589264
- Reversal of DDK-Mediated MCM Phosphorylation by Rif1-PP1 Regulates Replication Initiation and Replisome Stability Independently of ATR/Chk1. | Alver, RC., et al. 2017. Cell Rep. 18: 2508-2520. PMID: 28273463
- Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1. | Jin, S., et al. 2018. J Mol Med (Berl). 96: 513-525. PMID: 29713760
- A High-Throughput Assay for DNA Replication Inhibitors Based upon Multivariate Analysis of Yeast Growth Kinetics. | Ngo, M., et al. 2019. SLAS Discov. 24: 669-681. PMID: 30802412
- Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair. | Wienert, B., et al. 2020. Nat Commun. 11: 2109. PMID: 32355159
- Structural Basis for the Activation and Target Site Specificity of CDC7 Kinase. | Dick, SD., et al. 2020. Structure. 28: 954-962.e4. PMID: 32521228
- Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach. | Pulakuntla, S., et al. 2021. Virusdisease. 32: 690-702. PMID: 34307771
- Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth. | Chava, S., et al. 2022. iScience. 25: 104752. PMID: 35942091
- Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway. | Pauzaite, T., et al. 2022. Biomedicines. 10: PMID: 36009559
- Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. | Deng, L., et al. 2023. Cell Death Discov. 9: 40. PMID: 36725843
Inhibitor of:
Cdc6, Cdc7, cyclin H, DNA pol ε A, GTPBP6, HUNK, p63, Rab 12, Rab 36, RALGAPB, SEMA3F, and Vmn1r160.Activator of:
Elmo2, LOC553158, LOC642574, and Tiam2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
XL413, 5 mg | sc-474909 | 5 mg | $275.00 |